The global molecular diagnostics market is projected to grow from USD 18.26 billion in 2025 to USD 43.50 billion by 2035, with a CAGR of 9.07%. Growth is driven by increasing demand for early and accurate disease detection, rising prevalence of chronic diseases, and adoption of advanced technologies like PCR and next-generation sequencing. The U.S. market is expected to grow from USD 5.0 billion to USD 8.07 billion during the same period.
QIAGEN N.V. (QGEN)
Common Stock · Currency in USD · XNYS
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Company Info
SIC—
Composite FIGI—
CIK0001015820
IPOJun 28, 1996
Sector—
Highlights
Market Cap$8.46B
EPS—
P/E Ratio—
Revenue—
Gross Profit—
Net Income—
Employees5,654
WSO206,074,753
Phone—
Websitehttps://www.qiagen.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in QIAGEN N.V., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
QIAGEN N.V. (QGEN) has returned -8.74% so far this year and 4.38% over the past 12 months. Looking at the last ten years, QGEN has achieved an annualized return of 4.94%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
QGEN
1M-11.46%
6M-12.27%
YTD-8.74%
1Y4.38%
5Y-5.45%
10Y4.94%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of QIAGEN N.V. (QGEN) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 19.37% | -5.05% | -17.95% | 1.89% | ||||||||
| 2025 | -3.17% | -12.67% | 3.51% | 6.40% | 6.19% | 6.63% | 3.05% | -6.61% | -5.64% | 4.44% | 3.18% | -6.14% |
| 2024 | -1.74% | -1.79% | 0.26% | -1.60% | 2.58% | -4.64% | 9.07% | 2.17% | 1.95% | -7.41% | 1.28% | 2.41% |
| 2023 | -1.41% | -5.98% | -0.28% | -1.78% | 0.83% | -1.29% | 3.31% | -3.42% | -10.62% | -6.89% | 10.08% | 6.16% |
| 2022 | -10.21% | 0.16% | -2.25% | -7.78% | 0.90% | 2.92% | 6.25% | -8.88% | -8.06% | 3.91% | 12.13% | -0.04% |
| 2021 | 2.04% | -6.84% | -2.78% | -1.70% | 1.52% | -1.75% | 8.85% | 6.67% | -6.65% | 8.93% | -0.85% | 2.96% |
| 2020 | -1.49% | 6.09% | 14.22% | 3.45% | 5.04% | -1.59% | 16.03% | 2.19% | 2.41% | -9.69% | 0.54% | 11.01% |
| 2019 | 9.27% | 4.71% | 5.06% | -5.05% | -2.46% | 5.65% | -7.71% | -7.44% | -4.60% | -8.31% | 40.42% | -20.04% |
| 2018 | 8.31% | -1.98% | -2.48% | 1.27% | 11.28% | -1.09% | 1.18% | 1.86% | -1.69% | -5.00% | -3.77% | -5.15% |
| 2017 | -1.18% | -2.50% | 1.44% | 4.41% | 10.65% | -0.80% | -0.70% | -2.22% | -2.08% | 6.61% | -6.34% | -1.75% |
| 2016 | 2.00% | -4.34% | 1.39% | 21.93% | -0.34% | 3.90% | -10.60% | 12.06% | 2.86% |
Performance Indicators
The charts below present risk-adjusted performance metrics for QIAGEN N.V. (QGEN) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of QGEN compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current QIAGEN N.V. volatility is 1.84%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
News and Insights
The global molecular diagnostics market is projected to reach USD 33.51 billion by 2031, growing at a CAGR of 10.43% from 2026 to 2031. Growth is driven by increasing adoption of precision medicine, advancements in genomic testing technologies, and rising prevalence of infectious and chronic diseases. North America leads the market while Asia-Pacific is expected to be the fastest-growing region.
A comprehensive market research report on over-the-counter and direct-to-consumer infectious disease diagnostics forecasts significant growth through 2029, driven by rapid testing technologies, privacy concerns, and digital accessibility. The report analyzes market trends across 15 countries, covering respiratory, STD, UTI, and other infectious disease testing channels, with profiles of 70+ diagnostic companies.
The global automated sample preparation market is expected to expand at a 10.10% CAGR from 2025 to 2031, driven by pharmaceutical R&D investments, need for reproducibility, and AI/ML adoption. However, high initial costs and integration challenges with legacy systems remain significant barriers, particularly for smaller laboratories and SMEs.
The global microarrays market is projected to grow from USD 6.16 billion in 2025 to USD 10.72 billion by 2033, at a CAGR of 7.24%. Growth is driven by increasing adoption of genomics and proteomics research, drug discovery applications, and disease diagnostics. North America dominates with 43% market share, while Asia Pacific emerges as the fastest-growing region with a 9.54% CAGR.
The global next-generation sequencing (NGS) market is expected to grow from USD 14.25 billion in 2025 to USD 103.24 billion by 2035, at a CAGR of 21.9%. North America currently dominates with 50% market share, while Asia Pacific is the fastest-growing region. Oncology is the leading application segment, and consumables represent the largest product category. Key industry players are advancing NGS technology through strategic partnerships and innovative platforms.
German life sciences company Qiagen is exploring strategic options including a potential sale, with renewed takeover interest from multiple U.S.-based strategic buyers. The company has engaged advisers as its supervisory board evaluates preliminary approaches. CEO Thierry Bernard's announced departure is seen as removing a key obstacle to a deal. Qiagen has attracted acquisition interest multiple times in recent years, including failed attempts from Thermo Fisher Scientific (2020, ~$12 billion), BioMérieux (2021), and Bio-Rad Laboratories (2022).
The Middle East exosomes market is projected to grow from USD 3.07 million in 2024 to USD 20.03 million by 2033, at a CAGR of 23.38%. Growth is driven by increasing adoption of exosome-based diagnostics and therapeutics, rising biomedical R&D investment, and growing demand for liquid biopsy technologies. Key challenges include stringent regulatory requirements and high manufacturing costs.
The global reproductive genetics market is projected to grow from USD 7.31 billion in 2025 to USD 16.67 billion by 2032, with a CAGR of 12.5%. Growth is driven by rising demand for genetic testing, preimplantation genetic testing (PGT), and non-invasive prenatal testing (NIPT), though ethical and legal challenges continue to limit expansion. North America leads with 40.5% market share, while Asia Pacific is the fastest-growing region.
The global IVD diagnostic molecule raw enzymes market is projected to grow from USD 2.39 billion in 2024 to USD 4.73 billion by 2034, with a 7.13% CAGR. Key growth drivers include increasing chronic diseases, technological advancements in molecular diagnostics, and rising demand for precision medicine.